SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date Of Report (Date Of Earliest Event Reported): August 8, 2012
| NORTHWEST BIOTHERAPEUTICS, INC. |
(Exact Name of Registrant as Specified in Its Charter)
|
| |
|
| Delaware | | 0-33393 | | 94-3306718 |
| (State Or Other Jurisdiction Of Incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
___4800 Montgomery Lane, Suite 800, Bethesda, MD 20814___
(Address Of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including Area Code (240) 497-9024
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| £ | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| £ | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| £ | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| £ | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On August 8, 2012, Northwest Biotherapeutics, Inc. (the “Company”) issued a press release announcing that it is entering into amended agreements to double the production capacity in the U.S. for the manufacture of the Company’s DCVax®-L immune therapy for Glioblastoma multiforme patients and also announcing that the Company’s German partner, Fraunhofer IZI, has all of the necessary regulatory approvals and is fully operational for manufacturing of DCVaX®-L, and the Company’s UK Partner, Kings College Hospital, also has all of the necessary regulatory approvals and is in the final stages of preparations for such manufacturing. The Company further announced that both of its European partners will be able to deliver DCVaX®-L anywhere in Europe. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
Exhibit No. Description
99.1 Press Release of Northwest Biotherapeutics, Inc. dated August 8, 2012.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | NORTHWEST BIOTHERAPEUTICS, INC |
| | | |
| Dated: August 8, 2012 | By: | /s/ Linda Powers |
| | | Name: Linda Powers |
| | | Title: Chief Executive Officer and Chairman |
| | | |
